InvestorsHub Logo

shoondale

04/03/24 4:02 PM

#13381 RE: Lnut #13379

"certain deficiencies in its Premarket Approval (PMA) application that were identified by the FDA in 2021. These were largely related to the need for standardized procedures for our manufacturing process, and quality assurance procedures for finished, customer ready products."


First of all, this explains nothing about the 2017 PMA or 2022. Specifically what are these procedures in question? This could be anything. And what is this "largely"? What else did the FDA find? A link to the actual FDA document would be more reliable considering UHP's history of defrauding shareholders.
hhttps://www.sec.gov/files/litigation/complaints/2022/comp25413.pdf
Bearish
Bearish